News

Phase I contract supports the development of TRAUMAGEL for military personnel operating without immediate access to medical support NEW YORK, Oct. 26, 2026 – Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announces it has been selected by AFWERX for a Phase I Small Business Innovation Research (SBIR) contract focused on […]

New compact form factor will be introduced at EMS World 2026. It brings TRAUMAGEL hemostatic gel technology to a smaller footprint and easy one-handed use for first responders NEW YORK (September 30, 2026) – Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced the launch of TRAUMAGEL®’s next generation,

Clinical cases demonstrate successful use of TRAUMAGEL during tourniquet conversion in prolonged field care, including in gunshot wounds, industrial trauma and sharp-force injuries NEW YORK (July 7, 2026) — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced the publication of a peer-reviewed study evaluating the use of TRAUMAGEL®

NEW YORK—Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced two research presentations that will be featured at the 2026 Special Operations Medical Association (SOMA) Scientific Assembly April 27-May 1 in Raleigh, North Carolina, highlighting the real-world use of TRAUMAGEL® in prehospital trauma care settings. These presentations include a

This article was originally published on Inc. as part of an interview with Joe Landolina, Co-Founder and CEO of Cresilon. When he was a 17-year-old freshman at New York University, Joe Landolina saw a poster advertising the Tandon School of Engineering’s 2010 InnoVention Competition—where students pitch commercially viable prototypes of their inventions. He decided to sign up

This article was originally published on Adam Mendler’s blog as part of an interview with Joe Landolina, Co-Founder and CEO of Cresilon. Adam: Thanks again for taking the time to share your advice. First things first, though, I am sure readers would love to learn more about you. How did you get here? What experiences,

Ranked No. 1 in the medical devices category and No. 46 on Fast Company’s World’s 50 Most Innovative Companies list NEW YORK (March 25, 2026)—Cresilon has been named to Fast Company’s World’s 50 Most Innovative Companies of 2026. The company ranked No. 1 in the medical devices category and No. 46 overall. This marks the

NEW YORK—Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced that a retrospective clinical case series demonstrating the use of TRAUMAGEL®, in an emergency hemorrhagic trauma setting has been selected for a poster presentation at the 2026 Advanced Trauma Life Support® (ATLS®) Global Symposium taking place March 13-15 in

Contract awarded for products that bring improvement to healthcare industry New York (March 2, 2026)– Cresilon announced its revolutionary hemostatic gel TRAUMAGEL® has received an Innovative Technology contract from Vizient® the nation’s largest provider-driven healthcare performance improvement company. The contract was awarded based on review of TRAUMAGEL from hospital experts who serve on one of

NEW YORK (August 4, 2025) — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced that a case study demonstrating the clinical use of its FDA-cleared hemostatic medical device, TRAUMAGEL®, in an emergency hemorrhagic trauma setting has been selected for a poster presentation at the 2025 Military Health System